Merck Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer

Core Insights - Merck announced that the Phase 3 KEYNOTE-B96 trial met its secondary endpoint of overall survival for patients with platinum-resistant recurrent ovarian cancer [1] Group 1: Trial Details - The KEYNOTE-B96 trial, also known as ENGOT-ov65, studied the efficacy of KEYTRUDA® (pembrolizumab) in combination with chemotherapy (paclitaxel) with or without bevacizumab [1]